Alpha-1-microglobulin for use in the protection of kidneys in radionuclide therapy
AssigneeA1M Pharma AB
InventorsBo Akerstrom, Sven-Erik STRAND, Magnus Göran GRAM, Amanda Thuy TRAN
Life of this patent
Estimating the term…
Abstract
This invention relates to α1-microglobulin (A1M) for use in the diagnosis or treatment of malignancies requiring radionuclide diagnostics (RD), radionuclide therapy (RNT) or radioimmunotherapy (RIT), respectively, wherein A1M is used as a co-treatment to RD, RNT or RIT.
Claims21
1-28. (canceled)
A method of treating kidney injuries from a radionuclide or reducing renal side effects of a radionuclide in a subject undergoing radionuclide diagnostics (RD), radionuclide therapy (RNT), or radioimmunotherapy (RIT) for a malignancy, comprising administering α1-microglobulin (A1M) to a subject in need thereof, wherein the A1M has at least 95% sequence identity with SEQ ID NO:1 or SEQ ID NO:2.
A kit for reducing renal side effects of a radionuclide administered for radionuclide diagnostics (RD), radionuclide therapy (RNT), or radioimmunotherapy (RIT) of a malignancy, comprising
- A1M having at least 95% sequence identity with SEQ ID NO:1 or SEQ ID NO:2 and
- a compound labelled with a radionuclide, wherein the compound is a radionuclide diagnostic agent, a radionuclide therapeutic agent, or a radioimmunotherapeutic agent for a malignancy.
Dependencies are inferred from the claim text.